BIOPHARMA
By
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral Artery Disease Treatment in Europe?
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung Cancer?
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3 clinical trial included…
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After Phase 3 Success?
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity and safety in…
